# US 8,168,200 B2 · Vaccine against african horse sickness virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,168,200 B2
- Document ID: US8168200B2
- Status: Granted
- Kind: B2
- Application number: 12/604,048
- Filed: 2009-10-22
- Published: 2010-05-13
- Granted: 2012-05-01
- Earliest claimed: 2008-10-24
- Assignees: Merial Limited; The Regents of the University of California; University of Pretoria
- Inventors: Jules Maarten Minke; Jean-Christophe Audonnet; Alan John Guthrie; Nigel James MacLachlan; Jiansheng Yao
- Web page: https://patentgrep.com/patent/US8168200B2

## CPC

- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2720/12122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.

## Claims

### Claim 1

An immunogenic composition comprising
a recombinant poxvirus wherein the recombinant poxvirus comprises two nucleic acid molecules encoding polypeptides African Horse Sickness Virus (AHSV) VP2 and AHSV VP5; and wherein the composition is capable of eliciting a protective immune response in an equine animal.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the VP2 polypeptide is encoded by the sequence as set forth in SEQ ID NO:4 and the VP5 polypeptide is encoded by the sequence as set forth in SEQ ID NO:5.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the nucleic acid molecule comprises a sequence having at least 95% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:17.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the poxvirus comprises a nucleic acid sequence as set forth in SEQ ID NO:17.

### Claim 5 (depends on 1)

The composition of claim 1 further comprising a carboxypolymethylene adjuvant.

### Claim 6

An expression vector comprising one or more polynucleotide selected from the sequence as set forth in SEQ ID NO:4, the sequence as set forth in SEQ ID NO:5, and the combination of both.

### Claim 7 (depends on 6)

The vector of claim 6, wherein the the vector comprises both SEQ ID NOs: 4 and 5.

### Claim 8 (depends on 7)

The vector of claim 7, wherein the vector is a viral vector, and wherein the viral vector is an avipox, a canarypox or a fowlpox vector.

### Claim 9 (depends on 8)

The vector of claim 8, wherein the vector comprises both SEQ ID NO:4 and SEQ ID NO:5.

### Claim 10 (depends on 8)

The vector of claim 8, wherein the polynucleotide is operably linked to a promoter selected from the group consisting of H6 vaccinia promoter, I3L vaccinia promoter, 42K poxviral promoter, 7.5K vaccinia promoter, and Pi vaccinia promoter.

### Claim 11 (depends on 9)

The vector of claim 9, wherein SEQ ID NO:2 is operably linked to the H6 vaccinia promoter and SEQ ID NO:5 is operably linked to the 42K poxviral promoter.

### Claim 12 (depends on 6)

An isolated host cell transformed with the vector of claim 6.

### Claim 13 (depends on 1)

A method for inducing an immunological response in an animal comprising administering to the host an effective amount of the composition of claim 1.

### Claim 14 (depends on 1)

A method of vaccinating an animal susceptible to African Horse Sickness comprising administering at least one dose of the composition of claim 1.

### Claim 15 (depends on 1, 14)

The method of claim 14 further comprising administering at least a second dose of the composition of claim 1.